Target Name: LOC101928344
NCBI ID: G101928344
Review Report on LOC101928344 Target / Biomarker Content of Review Report on LOC101928344 Target / Biomarker
LOC101928344
Other Name(s): Uncharacterized LOC101928344, transcript variant X5 | Uncharacterized LOC101928344, transcript variant X6 | Uncharacterized LOC101928344, transcript variant X11 | LOC101928344 variant X6 | uncharacterized LOC101928344 | Uncharacterized LOC101928344, transcript variant X7 | Uncharacterized LOC101928344, transcript variant X4 | LOC101928344 variant X1 | Uncharacterized LOC101928344, transcript variant X2 | Uncharacterized LOC101928344, transcript variant X1 | LOC101928344 variant X3 | Uncharacterized LOC101928344, transcript variant X3 | LOC101928344 variant X2 | LOC101928344 variant X4 | LOC101928344 variant X11 | Uncharacterized LOC101928344, transcript variant X10 | LOC101928344 variant X10 | LOC101928344 variant X8 | Uncharacterized LOC101928344, transcript variant X9 | LOC101928344 variant X7 | LOC101928344 variant X9 | LOC101928344 variant X5 | Uncharacterized LOC101928344, transcript variant X8

LOC101928344: A Potential Drug Target or Biomarker

LOC101928344 (Uncharacterized LOC101928344, transcript variant X5) is a protein that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an intriguing candidate for research in these fields.

The LOC101928344 protein is a non-coding RNA molecule that is located in the nucleus of the human chromosome 19. It is characterized by a unique structure that consists of a long open reading frame (ORF) that is predominantly composed of spliced exons. The ORF is annotated by the UniProt database as a protein that is involved in various cellular processes, including cell adhesion, migration, and survival.

One of the most striking features of the LOC101928344 protein is its ability to self-assemble into distinct structural units, such as domains and subdomains. This self-assembly capability is unique among non-coding RNAs and has been observed to play a crucial role in the regulation of gene expression and protein function.

In addition to its self-assembly properties, the LOC101928344 protein is also known for its unique expression patterns. It has been shown to be highly expressed in a variety of tissues and cells, including cancer cells, neurodegenerative diseases, and autoimmune disorders. This differential expression pattern suggests that the LOC101928344 protein may be a useful biomarker for these diseases.

Furthermore, the LOC101928344 protein has also been shown to interact with various protein partners, including the transcription factor NF-kappa-B. This interaction suggests that the LOC101928344 protein may play a role in the regulation of gene expression and protein function, including the regulation of inflammation and immune responses.

In conclusion, the LOC101928344 protein is an intriguing candidate for drug targeting or biomarker research due to its unique structure and function. Its ability to self-assemble into distinct structural units and its differential expression patterns in various tissues suggest that it may be a useful target for small molecule inhibitors. Additionally, its interaction with the transcription factor NF-kappa-B also suggests that it may play a role in the regulation of gene expression and protein function. Further research is needed to fully understand the role of the LOC101928344 protein in these fields.

Protein Name: Uncharacterized LOC101928344

The "LOC101928344 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC101928344 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

LOC101928347 | LOC101928351 | LOC101928354 | LOC101928371 | LOC101928372 | LOC101928373 | LOC101928381 | LOC101928385 | LOC101928387 | LOC101928391 | LOC101928416 | LOC101928417 | LOC101928423 | LOC101928437 | LOC101928438 | LOC101928446 | LOC101928462 | LOC101928463 | LOC101928495 | LOC101928499 | LOC101928505 | LOC101928510 | LOC101928512 | LOC101928516 | LOC101928524 | LOC101928540 | LOC101928565 | LOC101928570 | LOC101928592 | LOC101928618 | LOC101928621 | LOC101928622 | LOC101928635 | LOC101928663 | LOC101928697 | LOC101928699 | LOC101928704 | LOC101928718 | LOC101928743 | LOC101928760 | LOC101928762 | LOC101928796 | LOC101928804 | LOC101928816 | LOC101928824 | LOC101928832 | LOC101928834 | LOC101928844 | LOC101928847 | LOC101928849 | LOC101928859 | LOC101928861 | LOC101928864 | LOC101928890 | LOC101928893 | LOC101928894 | LOC101928911 | LOC101928912 | LOC101928923 | LOC101928940 | LOC101928947 | LOC101928948 | LOC101928950 | LOC101928972 | LOC101929003 | LOC101929048 | LOC101929073 | LOC101929085 | LOC101929098 | LOC101929106 | LOC101929129 | LOC101929130 | LOC101929133 | LOC101929174 | LOC101929200 | LOC101929208 | LOC101929219 | LOC101929237 | LOC101929256 | LOC101929258 | LOC101929268 | LOC101929279 | LOC101929298 | LOC101929309 | LOC101929372 | LOC101929401 | LOC101929418 | LOC101929419 | LOC101929439 | LOC101929452 | LOC101929457 | LOC101929460 | LOC101929470 | LOC101929485 | LOC101929491 | LOC101929506 | LOC101929532 | LOC101929536 | LOC101929551 | LOC101929555